Pan-Cancer Analysis Identified C1ORF112 as a Potential Biomarker for Multiple Tumor Types

Chen, Jiaxuan; Mai, Haoming; Chen, Haitao; Zhou, Bin; Hou, Jinlin; Jiang, Deke

doi:10.3389/fmolb.2021.693651

Cited by 13 publications

(17 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using the HPA database (version 20.1; ), we also created a DDX21 protein and RNA expression graph in the “TISSUE” module after entering “DDX21.” ( 13 ). At the same time, we also made a single-cell-type expression map of DDX21 in the “SINGLE CELL” part (workflow diagram, Supplementary Figure S2 ) .…”

Section: Methodsmentioning

confidence: 99%

Pan-cancer analysis reveals DDX21 as a potential biomarker for the prognosis of multiple tumor types

Wang

Tian

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundDExD-box helicase 21 (DDX21) is an essential member of the RNA helicase family. DDX21 is involved in the carcinogenesis of various malignancies, but there has been no comprehensive research on its involvement in different types of cancer.MethodThis study used TCGA, CPTAC, GTEx, GEO, FANTOM5, BioGRID, TIMER2, GEPIA2, cBioPortal, STRING, and Metascape databases and Survival ROC software to evaluate DDX21 gene expression, protein expression, immunohistochemistry, gene mutation, immune infiltration, and protein phosphorylation in 33 TCGA tumor types, as well as the prognostic relationship between DDX21 and different tumors, by survival analysis and similar gene enrichment analysis. Furthermore, Cell Counting Kit-8 (CCK-8) and Transwell studies were employed to assess the effect of DDX21 expression on lung adenocarcinoma (LUAD) cell proliferation and migration.ResultThe DDX21 gene was highly expressed in most cancers, and overexpression was associated with poor overall survival (OS) and disease-free survival (DFS). DDX21 mutations were most common in uterine corpus endometrial carcinoma (UCEC; >5%), and DDX21 expression was positively correlated with the degree of infiltration of CAF and CD8+ cells in several tumor types. Numerous genes were co-expressed with DDX21. Gene enrichment analysis revealed close links between DDX21, RNA metabolism, and ribosomal protein production. In vitro analysis of LUAD cells showed that DDX21 expression was positively correlated with cell proliferation and migration capacity, consistent with prior bioinformatics studies.ConclusionsDDX21 is overexpressed in a variety of cancers, and overexpression in some cancers is associated with poor prognosis. Immune infiltration and DDX21-related gene enrichment analyses indicated that DDX21 may affect cancer development through mechanisms that regulate tumor immunity, RNA metabolism, and ribosomal protein synthesis. This pan-cancer study revealed the prognostic value and the oncogenic role of DDX21.

show abstract

Section: Methodsmentioning

confidence: 99%

Pan-cancer analysis reveals DDX21 as a potential biomarker for the prognosis of multiple tumor types

Wang

Tian

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…The multi-omics data of 33 tumor types from the TCGA project allow pan-cancer analyses of biomarkers and therapeutic targets using bioinformatic and statistic tools (3,(21)(22)(23)(24)(25). Our current study evaluated the clinical signi cance of SCL32A1, a key cuproptosis-regulatory gene, in various cancer types, and implicated a potentially substantial role of cuproptosis in cancers.…”

Section: Discussionmentioning

confidence: 98%

Systematic Pan-Cancer Analysis Identifies SLC31A1 as a Biomarker in Multiple Tumor Types

Kong

Ren

Jia

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Solute Carrier Family 31 Member 1 (SLC31A1) has recently been identified as a cuproptosis-regulatory gene. Recent studies have indicated that SLC31A1 may play a role in colorectal and lung cancer tumorigenesis. However, the role of SLC31A1 and its cuproptosis-regulatory functions in multiple tumor types remains to be further elucidated. Methods In this study, we used some website tools such as HPA, GEPIA2 and cBioPortal to estimate the expression, genetic alteration and prognostic in multiple cancer types. TIMER2 was used to evaluate the cancer-associated fibroblast infiltration. DAVID and BioGRID were used to conduct functional analysis and constructe the PPI network, respectively. Results In general, the TCGA datasets showed increased SLC31A1 expression in tumor tissues compared with non-tumor tissues in most tumor types. In patients with tumor types including Adrenocortical Carcinoma (ACC), Low-Grade Glioma (LGG), or Mesothelioma (MESO), higher SLC31A1 expression was correlated with shorter overall survival (OS) and disease-free survival (DFS). Moreover, the expression of SLC31A1 was also implicated to be positively correlated with the infiltration of fibroblasts into tumor tissues. Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that SLC31A1 co-expressed genes were involved in protein binding, integral components of the membrane, metabolic pathways, and protein processing in the endoplasmic reticulum. Protein-protein interaction network analysis showed that SLC31A1 interacted with Copper Chaperone for Superoxide Dismutase (CCS), and Erb-B2 Receptor Tyrosine Kinase 3 (ERBB3), which had been known to be associated with copper transportation and tumorigenesis. Conclusions These findings demonstrated that SLC31A1 is associated with multiple tumor types and prognosis. SLC31A1 may be a potential key biomarker and therapeutic target in cancers. As a result, it will be a novel new therapy for cancer patients to improve the prognosis of cancer patients.

show abstract

“…The “Immunity” module of TIMER2 ( )(accessed on 15 December 2022) was used to explore the correlation between the DMRT3 expression and the cancer-associated fibroblast infiltration using algorithms, such as the extended multidimensional immunome characterization (EPIC), microenvironmental cell population-counter (MCP-counter), cell type enrichment analysis (XCELL), and tumor immune dysfunction and exclusion (TIDE) algorithms, to explore the correlation between the DMRT3 expression and the cancer-associated fibroblast infiltration [ 23 ].…”

Section: Methodsmentioning

confidence: 99%

“…The UCSC Genome Browser (version: 2021 update) ( ) (accessed on 15 December 2022) was used to visualize the gene conversation of DMRT3 in vertebrates [ 23 ].…”

Section: Methodsmentioning

confidence: 99%

Comprehensive Analysis of DMRT3 as a Potential Biomarker Associated with the Immune Infiltration in a Pan-Cancer Analysis and Validation in Lung Adenocarcinoma

Yang

Liu

Jiang

et al. 2022

Cancers

View full text Add to dashboard Cite

Doublesex and Mab-3 related Transcription Factor 3 (DMRT3) is associated with the prognosis of some tumors. It is possible to explore the role of DMRT3 in the cancer process using bioinformatic approaches and experimental validation. We comprehensively explored the clinical and immunological characteristics of DMRT3. The DMRT3 expression is abnormal in human cancers and correlates with clinical staging. A high DMRT3 expression is significantly associated with poor overall survival (OS) in KIRC, KIRP, LUAD, and UCEC. Amplification was the greatest frequency of the DMRT3 alterations in pan-cancer. The OS was significantly lower in the DMRT3 altered group than in the DMRT3 unaltered group (P = 0.0276). The DMRT3 expression was significantly associated with MSI in three cancer types and TMB in six cancer types. The DMRT3 expression was significantly correlated with the level of the immune cell infiltration and the immune checkpoint genes. The DMRT3 was involved in some pathways in pan-cancer. DMRT3 may play a role in chemotherapy and may be associated with chemoresistance. A ceRNA network of KCNQ1OT1/miR-335-5p/DMRT3 was constructed in LUAD. DMRT3 was significantly upregulated in the LUAD cell lines. DMRT3 was aberrantly expressed in pan-cancer and may promote tumorigenesis and progression via different mechanisms. DMRT3 can be used as a therapeutic target to treat cancer in humans.

show abstract

Pan-Cancer Analysis Identified C1ORF112 as a Potential Biomarker for Multiple Tumor Types

Cited by 13 publications

References 33 publications

Pan-cancer analysis reveals DDX21 as a potential biomarker for the prognosis of multiple tumor types

Pan-cancer analysis reveals DDX21 as a potential biomarker for the prognosis of multiple tumor types

Systematic Pan-Cancer Analysis Identifies SLC31A1 as a Biomarker in Multiple Tumor Types

Comprehensive Analysis of DMRT3 as a Potential Biomarker Associated with the Immune Infiltration in a Pan-Cancer Analysis and Validation in Lung Adenocarcinoma

Contact Info

Product

Resources

About